Raltegravir 5 mg | 99.05%
TargetMol
Raltegravir is a pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.
More Information Supplier PageRaltegravir
Search Results
CNX-1351 10 mg | 98.83%
TargetMol
CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor.
More Information Supplier PageCNX-1351
GW9662 5 mg | 99.94%
TargetMol
GW9662 (TIMTEC-BB SBB006523) is a specific PPARγ antagonist (IC50: 3.3 nM, in a cell-free assay), with 100 to 1000-fold functional selectivity for PPARγ than PPARα/δ in cells.
More Information Supplier PageGW9662
GW9662 50 mg | 99.94%
TargetMol
GW9662 (TIMTEC-BB SBB006523) is a specific PPARγ antagonist (IC50: 3.3 nM, in a cell-free assay), with 100 to 1000-fold functional selectivity for PPARγ than PPARα/δ in cells.
More Information Supplier PageGW9662
GW9662 10 mg | 99.94%
TargetMol
GW9662 (TIMTEC-BB SBB006523) is a specific PPARγ antagonist (IC50: 3.3 nM, in a cell-free assay), with 100 to 1000-fold functional selectivity for PPARγ than PPARα/δ in cells.
More Information Supplier PageGW9662
GW9662 100 mg | 99.94%
TargetMol
GW9662 (TIMTEC-BB SBB006523) is a specific PPARγ antagonist (IC50: 3.3 nM, in a cell-free assay), with 100 to 1000-fold functional selectivity for PPARγ than PPARα/δ in cells.
More Information Supplier PageGW9662
CNX-1351 5 mg | 98.83%
TargetMol
CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor.
More Information Supplier PageCNX-1351
CNX-1351 50 mg | 98.83%
TargetMol
CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor.
More Information Supplier PageCNX-1351
LCL161 50 mg | 99.46%
TargetMol
LCL161, a SMAC mimetic, effectivity binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).
More Information Supplier PageLCL161
LCL161 5 mg | 99.46%
TargetMol
LCL161, a SMAC mimetic, effectivity binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).
More Information Supplier PageLCL161